Academics said the benefits of drugs such as Wegovy and Mounjaro – including for managing weight and blood sugar levels – are well known, but other health benefits of the popular drugs remain “unclear ...

More than one-third of people who helped develop the 2023 guidelines for treating children with obesity had undisclosed ...

Novo Nordisk holds 72% international and 50%+ U.S. market share in GLP-1 treatments, serving 46 million patients globally.

A new study from Mass Eye and Ear suggests that people taking semaglutide, a drug sold as Ozempic and Wegovy, may have a ...

Companies are selling personalized compounded drugs that combine weight loss and erectile dysfunction treatments, but is this safe? No one can say because it’s all “personalized” compounded drugs ...

Significant periods of weight regain were observed at eight, 12, and 20 weeks after stopping the anti-obesity medications.

Patients put on weight loss drugs like Ozempic and Wegovy may start regaining weight within weeks of discontinuing them, a ...

According to a recent study, nearly three in four Americans are overweight. Worse, this report predicts that for decades to ...

Eight weeks. That’s how long it takes, on average, for the pounds to begin creeping back after someone stops taking the world ...

Pfizer and Novo Nordisk have underperformed the market over the past year. Pharmaceutical giants Pfizer (NYSE: PFE) and Novo ...

With promising new obesity treatments in the pipeline, 24/7 Wall St. projects huge upside for Novo Nordisk stock through 2030 ...

Lawmakers are trying to restore access to GLP-1 weight loss drugs, like Ozempic and Wegovy, after Ohio removed medical ...